FAQ

AZD8055

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2018
0102020102018

Related topics

Related topics

1 relation

Broader (1)

mTOR Kinase Inhibitor AZD8055

Related mentions per year

Related mentions per year

2010-2018
201020122014201620182020
AZD8055
mTOR Kinase Inhibitor AZD8055

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.
The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described. An initial focus on… (More)
  • figure 2
  • table 1
  • figure 3
  • table 2
  • table 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
The serine/threonine kinase mammalian target of rapamycin (mTOR) is crucial for cell growth and proliferation, and is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
Background:This study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of the first-in-class dual… (More)
  • table 1
  • table 3
  • table 2
  • table 4
  • figure 1
Is this relevant?
2012
2012
Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).
The mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/AKT signaling pathways interact at multiple nodes in… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2012
2012
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.
BACKGROUND AZD8055 is a small molecule ATP-competitive inhibitor of the serine/threonine kinase mTOR that regulates cap-dependent… (More)
  • table I
  • figure 1
  • table II
  • figure 2
  • figure 3
Is this relevant?
2011
2011
mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.
mTOR is a central mediator of cancer cell growth, but it also directs immune cell differentiation and function. On this basis, we… (More)
Is this relevant?
2011
2011
First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.
3096 Background: AZD8055 is a dual mTORC1/mTORC2 inhibitor with properties that prevent the feedback activation of AKT seen with… (More)
Is this relevant?
2011
2011
Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1.
AZD8055 is an ATP-competitive inhibitor of mammalian target of rapamycin (mTOR) that forms two multiprotein complexes, mTORC1 and… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.
The mammalian target of rapamycin (mTOR) kinase forms two multiprotein complexes, mTORC1 and mTORC2, which regulate cell growth… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.
mTOR is a major biological switch, coordinating an adequate response to changes in energy uptake (amino acids, glucose), growth… (More)
Is this relevant?